Na Yeon Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Na Yeon Han has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ayman Muzammal
Division of Applied RI Korea Institute of Radiological and Medical Sciences Seoul Republic of Korea
1 shared publication Changkeun Im
Division of Applied RI Korea Institute of Radiological and Medical Sciences Seoul Republic of Korea
1 shared publicationChoong Mo Kang
Department of Nuclear Medicine Samsung Medical Center Seoul Republic of Korea
1 shared publication- Dongyoul Lee
Department of Physics and Chemistry Korea Military Academy Seoul Republic of Korea
1 shared publication - Jae Hun Ahn
Division of Applied RI Korea Institute of Radiological and Medical Sciences Seoul Republic of Korea
1 shared publication - Jeongyun Kim
Seoul National University
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Advanced Science
- p. e78419
Comparative Evaluation of Chelator‐Conjugated Peptides for Lead‐Labeled SSTR2‐Targeted Theranostics: Integrated Computational Modeling and Preclinical Validation
Lead‐212 ( 212 Pb)‐based targeted alpha therapy is a promising approach for somatostatin receptor subtype 2 (SSTR2)‐positive neuroendocrine tumors (NETs), yet chelator selection can markedly influence radiochemical and biological behavior. An integrated computational and experimental approach is used to compare DOTA‐, PSC‐, and DOTAM‐conjugated Tyr 3 ‐octreotate (TATE). Density functional theory (DFT) reveals distinct differences in lead(II) (Pb 2+ ) and bismuth(III) (Bi 3+ ) complexes, including interaction energies, coordination geometry, electrostatic properties, conformational flexibility, and kinetic accessibility. Experimental evaluation with 203 Pb demonstrates >98% radiolabeling efficiency and >97% apparent radiochemical stability for all three conjugates, while cellular uptake, biodistribution, single‐photon emission computed tomography/computed tomography (SPECT/CT) imaging, and dosimetry reveal marked chelator‐dependent differences. DOTAM‐TATE exhibits high and sustained tumor uptake but greater normal‐organ retention, whereas PSC‐TATE combines substantial tumor uptake with lower renal and systemic retention, resulting in the most favorable tumor‐to‐kidney profile. Together, these findings show that Pb‐chelator performance reflects a balance among thermodynamic stabilization, coordination kinetics, conformational adaptability, and physicochemical properties, providing mechanistic guidance for the rational design of Pb‐based targeted radiopharmaceuticals.
- 25 October 2026
- Published by Wiley in Advanced Science
- p. e78419
Open AccessComparative Evaluation of Chelator‐Conjugated Peptides for Lead‐Labeled SSTR2‐Targeted Theranostics: Integrated Computational Modeling and Preclinical Validation
Lead‐212 ( 212 Pb)‐based targeted alpha therapy is a promising approach for somatostatin receptor subtype 2 (SSTR2)‐positive neuroendocrine tumors (NETs), yet chelator selection can markedly influence radiochemical and biological behavior. An integrated computational and experimental approach is used to compare DOTA‐, PSC‐, and DOTAM‐conjugated Tyr 3 ‐octreotate (TATE). Density functional theory (DFT) reveals distinct differences in lead(II) (Pb 2+ ) and bismuth(III) (Bi 3+ ) complexes, including interaction energies, coordination geometry, electrostatic properties, conformational flexibility, and kinetic accessibility. Experimental evaluation with 203 Pb demonstrates >98% radiolabeling efficiency and >97% apparent radiochemical stability for all three conjugates, while cellular uptake, biodistribution, single‐photon emission computed tomography/computed tomography (SPECT/CT) imaging, and dosimetry reveal marked chelator‐dependent differences. DOTAM‐TATE exhibits high and sustained tumor uptake but greater normal‐organ retention, whereas PSC‐TATE combines substantial tumor uptake with lower renal and systemic retention, resulting in the most favorable tumor‐to‐kidney profile. Together, these findings show that Pb‐chelator performance reflects a balance among thermodynamic stabilization, coordination kinetics, conformational adaptability, and physicochemical properties, providing mechanistic guidance for the rational design of Pb‐based targeted radiopharmaceuticals.